Drug intelligence / Profile preview

Refnot

Development stage: Preclinical
Lead developer: Refnot-Pharm
Modality: Recombinant Proteins and Enzymes

Overview

Refnot is a recombinant drug combining Tumor Necrosis Factor (TNF) and Thymosin alpha-1. It has direct antitumor effects in vitro and in vivo on various tumor cell lines. The drug's mechanism includes inducing apoptosis or cell cycle arrest in tumor cells, activating coagulation and inflammatory responses, blocking angiogenesis, and modulating immune responses. It enhances the effectiveness of certain chemotherapeutic agents and has immunostimulatory properties.

Brand names: Refnot
Other names: Tumor Necrosis Factor-Thymosin alpha 1 recombinant

Targets

TNFR2 (Tumor necrosis factor receptor superfamily member 1B)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)

Beyond the preview

Go deeper on Refnot.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Refnot.

Explore the full profile